Xilio Therapeutics accelerates cancer immunotherapy with new masked T cell engager programs and $52m AbbVie collaboration

Xilio Therapeutics, Inc., a clinical-stage biotechnology company based in Waltham, Massachusetts, has announced the development of three new masked T cell engager programs designed to ... Read More